Stifel analysts increased their price target on Boston Scientific Corporation (NYSE:BSX) shares from $115.00 to $120.00, while reiterating a Buy rating for the medical device company. The adjustment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback